<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781270</url>
  </required_header>
  <id_info>
    <org_study_id>BECOME2</org_study_id>
    <nct_id>NCT04781270</nct_id>
  </id_info>
  <brief_title>mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases</brief_title>
  <official_title>mFOLFOXIRI Plus Bevacizumab Versus mFOLFOX6 Plus Bevacizumab for the First Line Treatment of RAS Mutant Unresectable Colorectal Liver-limited Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer patients with initially unresectable liver-only metastases may be cured&#xD;
      after downsizing of metastases by conversion therapy. However, the optimal regimen of&#xD;
      conversion therapy for RAS mutant patients has not been defined.&#xD;
&#xD;
      In this study colorectal cancer patients with initially unresectable liver-only metastases,&#xD;
      as prospectively confirmed by a local multidisciplinary team (MDT) according to predefined&#xD;
      criteria, will be tested for RAS and BRAF tumor mutation status. Patients with RAS mutant and&#xD;
      BRAF wild type will be randomised between modified FOLFOXIRI (mFOLFOXIRI) plus bevacizumab&#xD;
      and modified FOLFOX6 (mFOLFOX6) plus bevacizumab. Patient imaging will be reviewed for&#xD;
      resectability by MDT, consisting of at least one radiologist and three liver surgeons every&#xD;
      assessment. MDT review will be performed prior to randomization as well as during treatment,&#xD;
      as described in the protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be stratified for primary tumor location (right-sided or left sided), numbers&#xD;
      of liver metastases (&lt;5 or ≥5) and primary tumor resected or unresected.&#xD;
&#xD;
      Patients with RAS mutated primary tumors will be randomized between mFOLFOXIRI plus&#xD;
      bevacizumab (Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m^2&#xD;
      i.v. in 60 minutes, followed by oxaliplatin 85 mg/m^2 i.v. together with leucovorin 400&#xD;
      mg/m^2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 2400 mg/m^2 in&#xD;
      46 hours, every 2 weeks) or mFOLFOX6 plus bevacizumab (Bevacizumab 5 mg/kg in 15-30 minutes&#xD;
      i.v., followed by oxaliplatin 85 mg/m^2 i.v. together with leucovorin 400 mg/m^2 i.v. in 120&#xD;
      minutes, followed by bolus 5FU 400 mg/m^2, all on day 1, followed by continuous infusion of&#xD;
      5-fluorouracil 2400 mg/m^2 in 46 hours, every 2 weeks).&#xD;
&#xD;
      Patients will be evaluated every 8 weeks by MRI or CT scan for disease status. The assigned&#xD;
      systemic treatment should be continued for at least 6 months or earlier in case of&#xD;
      resectability, progression of disease, unacceptable toxicity, or patient refusal. If after 6&#xD;
      months MDT concludes that the patient is still not resectable, it is highly unlikely that&#xD;
      resectability will be achieved at all. Therefore the chemotherapy regimen may be reconsidered&#xD;
      after 6 months of treatment. These patients will continue with bevacizumab plus&#xD;
      fluoropyrimidine until progression or unacceptable toxicity.&#xD;
&#xD;
      In patients who will become resectable and undergo secondary surgery of liver metastases, the&#xD;
      total duration of preoperative and postoperative treatment together should be 6 months.&#xD;
      However, in these patients mFOLFOXIRI should not be continued after surgery and replaced by&#xD;
      mFOLFOX6. Bevacizumab will continued after surgery for both groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>conversion resection rate</measure>
    <time_frame>up to 6 months</time_frame>
    <description>R0 resection rate upon conversion treatment with chemotherapy plus bevacizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>from the first day of assigned treatment to death or last known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>from the first day of assigned treatment to progression or death whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (AE)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Patients will be evaluated for Adverse Events at the start of each treatment cycle according to CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complication</measure>
    <time_frame>After surgery during one month</time_frame>
    <description>Patients will be evaluated for surgical morbidity during 1 month. Postoperative morbidity will be scored according 'Clavien-Dindo Grade'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Response according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of no evidence of disease</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Response according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best deepness of response</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The maximum tumor shrinkage rates by Response Evaluation Criteria in Solid Tumors (RECIST) throughout the treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early tumor shrinkage</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>The rates of tumor shrinkage by RECIST at 8 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>mFOLFOXIRI+Bev</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive mFOLFOXIRI plus bevacizumab once every two weeks as the first-line treatment.&#xD;
Drug: mFOLFOXIRI plus Bevacizumab Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1). A local MDT will assess the efficiency every 4 cycles of the treatment. The maximum period of conversion therapy is 12 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFOX6+Bev</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive mFOLFOX6 plus bevacizumab once every two weeks as the first-line treatment.&#xD;
Drug: mFOLFOX6 Plus Bevacizumab mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1). A local MDT will assess the efficiency every 4 cycles of the treatment. The maximum period of conversion therapy is 12 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOXIRI regimen</intervention_name>
    <description>oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1</description>
    <arm_group_label>mFOLFOXIRI+Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX regimen</intervention_name>
    <description>oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1</description>
    <arm_group_label>mFOLFOX6+Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg on day 1</description>
    <arm_group_label>mFOLFOX6+Bev</arm_group_label>
    <arm_group_label>mFOLFOXIRI+Bev</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological proof of colorectal adenocarcinoma;&#xD;
&#xD;
          -  Age ≥ 18 years and ≤75 years;&#xD;
&#xD;
          -  Simultaneous liver-limited metastases;&#xD;
&#xD;
          -  Initially unresectable liver metastases determined by a local MDT;&#xD;
&#xD;
          -  RAS mutation and BRAF V600E wild-type;&#xD;
&#xD;
          -  At least one measurable liver metastasis;&#xD;
&#xD;
          -  Initially resectable primary tumor or primary tumor already resected;&#xD;
&#xD;
          -  World Health Organization (WHO) performance status 0-1;&#xD;
&#xD;
          -  Life expectancy ≥ 3 months;&#xD;
&#xD;
          -  Adequate hematologic function: absolute neutrophil count (ANC)≥1.5×109/l,&#xD;
             platelets≥100×109/l, and hemoglobin(HB) ≥ 9g/dl;&#xD;
&#xD;
          -  Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, serum transaminases ≤&#xD;
             5x upper limit of normal(ULN), and serum creatinine ≤ 1.5x ULN and creatinine&#xD;
             clearance ≥ 30 ml/min;&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous systemic treatment for metastatic disease;&#xD;
&#xD;
          -  Previous surgery for metastatic disease;&#xD;
&#xD;
          -  Extrahepatic metastases;&#xD;
&#xD;
          -  Unresectable primary tumor;&#xD;
&#xD;
          -  Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive&#xD;
             heart failure, CVA) within 12 months before randomisation;&#xD;
&#xD;
          -  Acute or subacute intestinal obstruction;&#xD;
&#xD;
          -  Second primary malignancy within the past 5 years;&#xD;
&#xD;
          -  Drug or alcohol abuse;&#xD;
&#xD;
          -  No legal capacity or limited legal capacity;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Uncontrolled hypertension, or unsatisfactory blood pressure control with ≥3&#xD;
             antihypertensive drugs;&#xD;
&#xD;
          -  Peripheral neuropathy;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianmin Xu, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianmin Xu, MD, Ph.D.</last_name>
    <phone>021-64041990</phone>
    <email>xujmin@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wentao Tang, MD, Ph.D.</last_name>
    <phone>021-64041990</phone>
    <email>tangwt1988@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianmin Xu, M.D. Ph.D</last_name>
      <email>xujmin@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Wentao Tang, M.D. Ph.D</last_name>
      <email>tangwt1988@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kefeng Ding, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shan Zeng, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhenning Wang, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tao Zhang, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lechi Ye, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chunkang Yang, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guiying Wang, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

